FDA Approves OPDIVO — E.R. Squibb & Sons, L.L.C.
The FDA has approved Opdivo (nivolumab) from E.R. Squibb & Sons, L.L.C., a key asset for the manufacturer's oncology franchise that is poised to bolster market share within the expanding immuno-oncology sector.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day